Welcome!

News Feed Item

Positive Results From Multi-Centre, Prospective Clinical Trial for Diagnosis of Basal Cell Carcinoma Using Michelson Diagnostics' VivoSight OCT Presented at AAD

ORPINGTON, England, March 21, 2014 /PRNewswire/ --



Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, today announces positive results from the successfully completed multi-centre, prospective clinical trial for the diagnosis of basal cell carcinoma using VivoSight OCT to be presented at the upcoming American Academy of Dermatology's 72nd Annual Meeting (AAD) in Denver, Colorado, 21-25 March 2014.

Papers by Professor Dr. med. Julia Welzel, Dr. med. Martina Ulrich discussing results from the clinical study will be presented in the AAD Conference Session F153 "Non-Invasive Imaging in Dermatology" on Tuesday, 25 March at 1.00pm.

The presented results support Michelson Diagnostics vision that its VivoSight OCT system has the potential to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect the skin, and in particular non-melanoma skin cancer.  For further information come and meet the team at the Michelson Diagnostics booth, number 2255 - http://show.aad.org/annual14/EC/forms/attendee/indexTab.aspx

The AAD Annual Meeting is the largest dermatology meeting in the world, with approximately 20,000 delegates expected from more than 90 countries.  The AAD supports the highest-quality patient care by developing and presenting information that enhances continuing education in dermatology.  AAD meetings offer the latest on the diagnosis, prevention, and treatment of dermatologic disease from the foremost experts in the field.

All abstracts and details on timings can be accessed through the AAD website: http://www.aad.org/meetings/2014-annual-meeting.

The title, timing and location of the poster presentations are as follows:

    Abstract         F153

    Title:           Non-Invasive Imaging in Dermatology
                     Orit Markowitz, MD, FAAD; Robert Bard, MD; Theresa Cao, DO;
                     Gerald Messer; Daniel M. Siegel, MD, MS, FAAD ; Dan Sperling,
    Authors:         MD; Martina Ulrich, MD; Julia Welzel, MD
                     This forum will address the utility of some of the most
                     recent dermatologic non-invasive imaging devices including
                     optical coherence tomography, the new handheld confocal
                     microscope, 3-D high resolution ultrasound, MRI as well as
                     MRI/US fusion. The attendee will be able to recognize basic
                     images with these devices, how they differ and understand
                     what role each plays in daily practice as well as in basic
                     dermatologic research. The most recent imaging advances
                     ranging from measuring in transit melanoma metastases,
                     visualization of field cancerization, monitoring non-invasive
                     treatment of skin cancer and even diagnosis of onychomycosis
    Session Info:    will be discussed.
    Day/Date:        Tuesday 25 March 2014
    Session Time:    1pm - 3pm Eastern Time
    Location :       Room 705/707

For  further  information

Notes  to  editors

About  Michelson  Diagnostics  and  the  VivoSight  System

Michelson Diagnostics has developed a world-leading, patented, medical imaging technology, known as multi-beam Optical Coherence Tomography ('OCT'), that uses an advanced laser scanner to 'see' into tissue with unprecedented image resolution and quality of image.  Multi-beam OCT has many potential clinical applications, but we are currently focusing on dermatology.

Our vision is for our VivoSight OCT system to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body.  We currently generate revenues from our first commercial application of VivoSight, which is in the diagnosis of non-melanoma skin cancer (NMSC).

VivoSight has regulatory clearance in Europe, USA and Australia, for use by trained clinicians in their assessment of the patient's medical condition.  We have launched VivoSight in Germany where the VivoSight scan is reimbursed for patients with private healthcare insurance.

The Company, based in Orpington, Kent, was founded in 2006 and has 18 employees.  It has sales offices in Germany and USA.  It has been supported through funding from a syndicate of Venture Capital, corporate and private investors including Octopus, Catapult Ventures and Angel Investors.  

For more information about Michael Diagnostics, see http://www.michelsondiagnostics.com.

Michelson Diagnostics
Tel: +44(0)20-8308-1695
Jon Holmes, Chief Executive Officer    

FTI Consulting
Tel: +44(0)20-7831-3113
Simon Conway / Mo Noonan / Victoria Foster Mitchell

SOURCE Michelson Diagnostics

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.